A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.

Br J Cancer · 2006 · PMC2361232 · PMID 16552439

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In randomised phase III trials in advanced gastric cancer, FP led to improved response rates compared with 5-FU, doxorubicin and mitomycin (FAM) or 5-FU single-agent therapy ( Kim et al , 1993 ), and showed a trend towards improved response rates compared with 5-FU, doxorubicin and methotrexate (FAMTX) or etoposide, leucovorin and bolus 5-FU (ELF) ( Vanhoefer et al , 2000 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.